ストックスクリーナーアプリを入手
20.96
1.09%
-0.23
前日終値:
$21.19
開ける：
$20.84
24時間の取引高:
201.69K
Relative Volume:
1.23
時価総額：
$805.12M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+20.81%
1か月 パフォーマンス:
+21.72%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$20.28
$21.26
1週間の範囲:
$16.14
$21.94
52週間の値動き範囲:
$7.255
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
名前
Sionna Therapeutics Inc
セクター
電話
617-819-2020
住所
21 HICKORY DRIVE, SUITE 500, WALTHAM
SION を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
20.96 | 805.12M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-04 | 開始されました | Guggenheim | Buy |
| 2025-03-04 | 開始されました | Stifel | Buy |
| 2025-03-04 | 開始されました | TD Cowen | Buy |
Sionna Therapeutics Inc (SION) 最新ニュース
Sling Therapeutics, Inc. Appoints Ken Lock as Chief Commercial Officer - MarketScreener
Sionna Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Sionna Therapeutics Holds Annual Stockholders Meeting - TipRanks
Sionna Therapeutics reports annual meeting results - Investing.com
Sionna's experimental CFTR modulators show promise in preclinical tests - Cystic Fibrosis News Today
Odyssey Therapeutics pulls plug on IPO plans - The Business Journals
Odyssey Ends Quest for Nasdaq, Pulls IPO Application After Nearly 5 Months - BioSpace
Odyssey pulls back from IPO plans as public markets remain frozen - Endpoints News
Sionna Therapeutics advances CF treatment with new data By Investing.com - Investing.com South Africa
Sionna Therapeutics advances CF treatment with new data - Investing.com India
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model - GlobeNewswire
Breakthrough Clinical Data: New Dual Therapy Achieves Complete CFTR Correction in Cystic Fibrosis Model - Stock Titan
NBD1 stabilizers safe in healthy volunteers, Sionna says - Cystic Fibrosis News Today
Petri Dish: PepGen halts work on Duchenne drug; Needham biotech announces layoffs - The Business Journals
2 Soaring Stocks Wth More Upside Potential - AOL.com
Transcript : Sionna Therapeutics, Inc.Special Call - marketscreener.com
Sionna advances cystic fibrosis treatments to new trials By Investing.com - Investing.com South Africa
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial - Benzinga
Stifel analysts reiterate buy rating on Sionna Therapeutics stock By Investing.com - Investing.com Canada
Sionna Therapeutics Announces Positive Phase 1 Results For SION-719, SION-451 In Cystic Fibrosis - Nasdaq
Sionna advances cystic fibrosis treatments to new trials - Investing.com Australia
Sionna Therapeutics Reports Positive Phase 1 Trial Results - TipRanks
Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis - The Manila Times
Sionna Therapeutics Announces Positive Phase 1 Data For Nbd1 Stabilizers Sion-719 And Sion-451 And Advances Both Programs In Clinical Development For Cystic Fibrosis - marketscreener.com
Sionna Therapeutics Announces Positive Phase 1 Data for - GlobeNewswire
Sionna selects which cystic fibrosis drug it will study in a mid-stage test - Endpoints News
Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
3 No-Brainer Healthcare Stocks to Buy in June - AOL.com
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 6% – Here’s What Happened - Defense World
Why Summit Therapeutics Plunged Today - AOL.com
3 High-Flying Stocks That Could Soar Even More - AOL.com
Sionna Therapeutics to Present Preclinical Data on CFTR Modulators at European Cystic Fibrosis Conference - Nasdaq
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference - GlobeNewswire
Sionna Therapeutics (NASDAQ:SION) Shares Gap Down Following Weak Earnings - Defense World
Sionna Therapeutics Phase 1 Topline Data For Nbd1 Stabilizers Sion-719 & Sion-451 Expected This Quarter - marketscreener.com
Sionna Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire
Private equity firms invested in Sionna Therapeutics, Inc. (NASDAQ:SION) copped the brunt of last week's US$56m market cap decline - simplywall.st
While individual investors own 26% of Sionna Therapeutics, Inc. (NASDAQ:SION), private equity firms are its largest shareholders with 56% ownership - Yahoo Finance
Why Vertex Pharmaceuticals Stock Is a Screaming Buy on the Dip - AOL.com
Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 - The Manila Times
Revolutionary Cystic Fibrosis Treatment Developer Sionna Takes Stage at Major Healthcare Conference - Stock Titan
2 Beaten-Down Stocks With Incredible Upside Potential - AOL.com
OrbiMed-backed biotech looks to challenge Vertex in cystic fibrosis by 'drugging the undruggable' - Endpoints News
Alcoa Posts Weak Revenue, Joins QXO And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Q1 IPOs Rise From Q4, But Unstable Markets Could Slow New Offerings - insights.citeline.com
In 2025, biotech IPOs were supposed to bounce back. It hasn't happened yet. - The Business Journals
Sionna Therapeutics (NASDAQ:SION) Trading Down 4.2%What's Next? - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Reaches New 1-Year Low on Disappointing Earnings - Defense World
Stifel maintains Buy rating on Sionna Therapeutics stock at $32 target - Investing.com Australia
Sionna Therapeutics Inc (SION) 財務データ
Sionna Therapeutics Inc (SION) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Sionna Therapeutics Inc (SION) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| TPG GP A, LLC | 10% Owner |
Feb 10 '25 |
Buy |
18.00 |
1,125,000 |
20,250,000 |
6,684,962 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Feb 10 '25 |
Buy |
18.00 |
1,125,000 |
20,250,000 |
6,923,365 |
| ORBIMED ADVISORS LLC | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Thompson Peter A. | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Booth Bruce | Director |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
1.08%
2.14%
大文字化:
|
ボリューム (24 時間):